RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors (Q35721081)

9 August 2017

title

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors (English)

1 reference

9 August 2017

0 references

Kristin Ardlie

1 reference

9 August 2017

Caroline Robert

0 references

Grant A McArthur

0 references

Antje Sucker

1 reference

9 August 2017

Dirk Schadendorf

1 reference

9 August 2017

Levi A Garraway

1 reference

9 August 2017

Patrick A Oberholzer

1 reference

9 August 2017

Damien Kee

1 reference

9 August 2017

Piotr Dziunycz

1 reference

9 August 2017

Nyam Kamsukom

1 reference

9 August 2017

Robert Jones

1 reference

9 August 2017

Christine Roden

1 reference

9 August 2017

Clinton J Chalk

1 reference

9 August 2017

Emanuele Palescandolo

1 reference

9 August 2017

Adriano Piris

1 reference

9 August 2017

Laura E MacConaill

1 reference

9 August 2017

Günther F L Hofbauer

1 reference

9 August 2017

language of work or name

English

0 references

publication date

7 November 2011

1 reference

Journal of Clinical Oncology

9 August 2017

published in

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

316-321

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Sorafenib‐induced premalignant and malignant skin lesions

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Profiling critical cancer gene mutations in clinical tumor samples

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

The histologic spectrum of epithelial neoplasms induced by sorafenib

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

CD30+ cells in regressing keratoacanthoma and in non-keratoacanthomatous squamous cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Cutaneous side-effects of kinase inhibitors and blocking antibodies

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Non-melanoma skin cancer: what drives tumor development and progression?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

PTCH mutations in squamous cell carcinoma of the skin.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Codon 12 Harvey-ras mutations are rare events in non-melanoma human skin cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Genetic alterations during colorectal-tumor development

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Oncogene activation in human benign tumors of the skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

ras oncogenes in human cancer: a review

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

A genetic model for colorectal tumorigenesis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

RAF inhibition and induction of cutaneous squamous cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

The immunopathology of regression in benign lichenoid keratosis, keratoacanthoma and halo nevus

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Alterations of p53 gene and Ha-ras gene are independent events in solar keratosis and squamous cell carcinoma.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

High-throughput oncogene mutation profiling in human cancer

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269955

Quantitation of S100 protein-positive cells in inflamed and non-inflamed keratoacanthoma and squamous cell carcinoma

15 November 2018

1 reference

12 December 2020

Low incidence of c-Ha-ras gene mutations in benign and malignant cutaneous lesions from transplant recipients

1 reference

12 December 2020

Activated ras Genes Occur in Human Actinic Keratoses, Premalignant Precursors to Squamous Cell Carcinomas

1 reference

12 December 2020

High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer

1 reference

12 December 2020

A comparative study of granzyme B expression in keratoacanthoma and squamous cell carcinoma

1 reference

12 December 2020

Actinic keratosis: facts and controversies

1 reference

12 December 2020

Keratoacanthoma: facts and controversies

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2011.36.7680

1 reference

9 August 2017

1 reference

9 August 2017

1 reference